| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/16/2002 | US6372494 Culturing fibroblast cells in three-dimensions in a cell culture medium; removing conditioned medium from the cultured cells; combining conditioned medium with a pharmaceutically acceptable carrier |
| 04/16/2002 | US6372490 Nucleic acid encoding the MDM interacting protein |
| 04/16/2002 | US6372487 Polynucleotides encoding peptide release factor, prfC (RF-3), a GTP-binding protein |
| 04/16/2002 | US6372468 Useful in the development of human therapeutics and diagnostic formulations |
| 04/16/2002 | US6372431 Mammalian toxicological response markers |
| 04/16/2002 | US6372260 Incorporation of active substances in carrier matrixes |
| 04/16/2002 | US6372251 Bioavailability |
| 04/16/2002 | US6372229 Curing water soluble proteinaceous material and di- or polyaldehyde |
| 04/16/2002 | US6372217 Methods for the treatment of CD7+ viral infection with TXU-7-PAP |
| 04/16/2002 | US6372205 Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs |
| 04/16/2002 | US6372197 Methods and compositions using norastemizole in combination with leukotriene inhibitors |
| 04/16/2002 | US6372185 Liquid chemical distribution method and apparatus |
| 04/16/2002 | CA2266629C Taste-masked microcapsule compositions and methods of manufacture |
| 04/16/2002 | CA2186037C New pharmaceutical formulation and process |
| 04/16/2002 | CA2184195C Screening method for identifying ligands for target proteins |
| 04/16/2002 | CA2046607C Inhibiting transformation of cells having elevated purine metabolic enzyme activity |
| 04/15/2002 | WO2002030514A2 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors |
| 04/15/2002 | CA2421622A1 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors |
| 04/11/2002 | WO2002029418A1 Selective anxiolytic therapeutic agents |
| 04/11/2002 | WO2002029086A2 Nucleic acid sequences differentially expressed in cancer tissue |
| 04/11/2002 | WO2002029061A2 G-protein coupled receptors |
| 04/11/2002 | WO2002029060A2 Hematopoietin receptors hpr1 and hpr2 |
| 04/11/2002 | WO2002029055A2 Carbohydrate-associated proteins |
| 04/11/2002 | WO2002029044A2 Modulation of the transcription of pro-inflammatory gene products |
| 04/11/2002 | WO2002029036A2 Lipid metabolism enzymes |
| 04/11/2002 | WO2002029031A2 Isoprenoid-dependent ras anchorage (idra) proteins |
| 04/11/2002 | WO2002029013A1 Culture of goblet cells |
| 04/11/2002 | WO2002028906A2 Regulation of human sphingosine kinase-like protein |
| 04/11/2002 | WO2002028897A2 Human g-protein coupled receptor and uses thereof |
| 04/11/2002 | WO2002028895A2 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator |
| 04/11/2002 | WO2002028862A2 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 04/11/2002 | WO2002028831A1 Inhibitors of prenyl-protein transferase |
| 04/11/2002 | WO2002028825A2 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors |
| 04/11/2002 | WO2002028521A1 Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation |
| 04/11/2002 | WO2002028440A1 Methods and compositions for modulating t cell activation and uses thereof |
| 04/11/2002 | WO2002028434A2 Use of a ppar delta activator for treating inflammatory conditions |
| 04/11/2002 | WO2002028433A2 Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition |
| 04/11/2002 | WO2002028432A2 Stem cell-based methods for preventing and treating tumor |
| 04/11/2002 | WO2002028430A2 Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| 04/11/2002 | WO2002028425A2 Methods for treating muscle injuries |
| 04/11/2002 | WO2002028414A1 Compositions and methods for wt1 specific immunotherapy |
| 04/11/2002 | WO2002028409A2 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| 04/11/2002 | WO2002028408A2 Compositions and methods for the transport of biologically active agents across cellular barriers |
| 04/11/2002 | WO2002028402A1 Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 04/11/2002 | WO2002028401A1 Fluoride as a chemoprotective and chemotherapeutic agent for cancer in mammals |
| 04/11/2002 | WO2002028394A1 Use of medicaments |
| 04/11/2002 | WO2002028393A1 Use of neuropeptide-y antagonists in treatment of alcoholism |
| 04/11/2002 | WO2002028390A1 Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| 04/11/2002 | WO2002028388A2 Use of mek1 inhibitors as protective agents against damage due to ischemia |
| 04/11/2002 | WO2002028387A1 Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| 04/11/2002 | WO2002028381A2 Methods of inducing cancer cell death and tumor regression |
| 04/11/2002 | WO2002028379A2 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
| 04/11/2002 | WO2002028378A1 Combination particles for the treatment of asthma |
| 04/11/2002 | WO2002028377A1 Ihnalation particles incorporating a combination of two or more active ingredients |
| 04/11/2002 | WO2002028368A1 New combination for the treatment of asthma |
| 04/11/2002 | WO2002028355A2 Methods and compositions for enhancing angiogenesis |
| 04/11/2002 | WO2002028349A2 Method of treating cancer using dithiocarbamate derivatives |
| 04/11/2002 | WO2002028346A2 Association of the cb1 receptor antagonist and sibutramin, for treating obesity |
| 04/11/2002 | WO2002028345A2 Aldehyde-releasing compounds |
| 04/11/2002 | WO2002028270A2 The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor |
| 04/11/2002 | WO2002012275A3 Lat peptides and their use in assays for identifying immunosuppressants |
| 04/11/2002 | WO2002003911A3 Prevention and treatment of alzheimer's disease |
| 04/11/2002 | WO2001092581A8 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 04/11/2002 | WO2001087342A3 Delivery devices for treatment of vascular disease |
| 04/11/2002 | WO2001085935A3 Endothelial differentiation gene 6-like g protein coupled receptor |
| 04/11/2002 | WO2001083031A3 Topical composition for the treatment of psoriasis and related skin disorders |
| 04/11/2002 | WO2001082868A3 A medicinal aerosol formulation |
| 04/11/2002 | WO2001080864A3 Chemical modification of mammalian urine and blood |
| 04/11/2002 | WO2001077079A3 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| 04/11/2002 | WO2001075107A3 Use of p-selectin glycoprotein ligand-1 (psgl-1) and fragments thereof for the inhibition of thrombosis |
| 04/11/2002 | WO2001072780A3 Polynucleotides for diagnosing mammary gland cancer |
| 04/11/2002 | WO2001070174A3 Vegf-modulated genes and methods employing them |
| 04/11/2002 | WO2001068137A3 Compositions for regulating memory consolidation |
| 04/11/2002 | WO2001066147A3 Antimicrobial compounds and formulations |
| 04/11/2002 | WO2001066085A3 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/11/2002 | WO2001060844A3 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system |
| 04/11/2002 | WO2001059153A3 Method for identifying substances which modulate the activity of hyperpolarisation-activated cation channels |
| 04/11/2002 | WO2001058240A3 Photodynamic therapy for treating conditions of the eye |
| 04/11/2002 | WO2001053835A3 Methods for detecting cancer of the central nervous system |
| 04/11/2002 | WO2001053348A3 Human polypeptides related to the vanilloid and trp families of cation channel proteins and nucleic acids encoding them |
| 04/11/2002 | WO2001051673A8 Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission |
| 04/11/2002 | WO2001049278A3 Compounds and compositions for use in inhibiting endoparasitic fatty acid biosynthesis |
| 04/11/2002 | WO2001045678A3 Medicament, a method for its production and the use thereof |
| 04/11/2002 | WO2001028589A3 Shaped body comprising an amphiphilic outer phase and a lipophilic inner phase |
| 04/11/2002 | WO2001010906A9 Crystallization and structure determination of staphylococcus aureus elongation factor p |
| 04/11/2002 | WO2000058523A9 Glucocorticoid receptor agonist and decreased pp5 |
| 04/11/2002 | WO2000057907A9 Multivalent dengue virus vaccine |
| 04/11/2002 | WO2000052210A3 Methods for targeting rna molecules |
| 04/11/2002 | WO2000047214A9 Anti-resorptive bone cements and allogeneic, autografic, and xenografic bone grafts |
| 04/11/2002 | WO2000036103A9 Cytokine receptor chain |
| 04/11/2002 | US20020042926 Ovary-specific genes and proteins |
| 04/11/2002 | US20020042554 Cardiac disease treatment method |
| 04/11/2002 | US20020042513 Therapeutic compounds |
| 04/11/2002 | US20020042505 Novel human ion channel protein and polynucleotides encoding the same |
| 04/11/2002 | US20020042434 Pharmaceutical composition |
| 04/11/2002 | US20020042432 Synergistic mixtures |
| 04/11/2002 | US20020042419 Administering growth hormone secretagogue |
| 04/11/2002 | US20020042415 Dipeptide derivatives |
| 04/11/2002 | US20020042405 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| 04/11/2002 | US20020042401 Use of sex steroids function modulators to treat wounds and fibrotic disorders |